Orphan Drug Designation

Also called ODD · orphan designation

Orphan Drug Designation (ODD) is granted by the FDA to drugs intended to treat rare diseases affecting fewer than 200,000 people in the US. It provides development incentives including 7-year market exclusivity, tax credits, and accelerated review. Thymosin α1 holds orphan designation in the US for certain indications.